Overview

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Status:
Completed
Trial end date:
2017-09-25
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Radium Ra 223 dichloride
Succinylcholine